Cargando…
Roflumilast Attenuates Doxorubicin-Induced Cardiotoxicity by Targeting Inflammation and Cellular Senescence in Cardiomyocytes Mediated by SIRT1
BACKGROUND AND PURPOSE: Cardiotoxicity is an important side effect of the treatment of a malignant tumor with Doxorubicin. Currently, decreasing the dosage of Doxorubicin to alleviate the side effects on cardiac function is the common method to deal with the cardiotoxicity induced by Doxorubicin. Th...
Autores principales: | Zhang, Sheng, Wu, Peng, Liu, Jiabao, Du, Yingqiang, Yang, Zhijian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810683/ https://www.ncbi.nlm.nih.gov/pubmed/33469262 http://dx.doi.org/10.2147/DDDT.S269029 |
Ejemplares similares
-
Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity
por: Chen, De-Shu, et al.
Publicado: (2022) -
Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes
por: Zhao, Liqun, et al.
Publicado: (2017) -
Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis
por: Chen, Meicong
Publicado: (2023) -
Peroxiredoxin-1 Overexpression Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Oxidative Stress and Cardiomyocyte Apoptosis
por: Jiang, Lai, et al.
Publicado: (2020) -
Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
por: Gauvreau, Gail M, et al.
Publicado: (2011)